Benzinga's Top #PreMarket Losers

by Monica Gerson, Benzinga Staff Writer

March 23, 2015 8:15 AM | 1 min read | Make a Comment

MEI Pharma, Inc.MEIP

fell 62.90% to $2.33 in pre-market trading on failed Pracinostat and azacitidine Phase II study.

Vertex Pharmaceuticals IncorporatedVRTX

shares declined 9.16% to $119.00 in pre-market trading after the company reported data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor.

Gilead Sciences Inc. GILD

shares dropped 2.85% to $99.38 in pre-market after rising 0.84% on Friday.

Carnival Corporation CCL

shares fell 1.98% to $45.95 in pre-market trading. Deutsche Bank downgraded Carnival from Buy to Hold.

Biogen Idec Inc. BIIB

slipped 1.47% to $469.00 in pre-market trading. The company reported that effective today, Biogen Idec will be known simply as Biogen. Stifel Nicolaus downgraded Biogen from Buy to Hold.

Market News and Data brought to you by Benzinga APIs

Posted In: News Movers & Shakers Pre-Market Outlook Markets Top Losers

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!